About us

MaaT Pharma

MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.

 

OUR VISION

Be the industry leader for the treatment of Gut Microbiota alteration (so-called dysbiosis) using patient-specific microbiotherapy in patients with serious medical conditions.

OUR MISSION

Our goal is to become one of the leaders in development of drugs aiming at preventing and treating dysbiosis-related diseases by using the clinical promise of Autologous Fecal Microbiota Transplant.

Our initial development is targeting the treatment of infectious diseases for frail patients in the field of onco-hematology. This development is our cornerstone towards many other indications.

Innovation is at the epicenter of MaaT Pharma’s strategy and we rely on the commitment of a team of outstanding Gut Microbiome medico-scientific experts to support our developments.

We are MaaT Pharma (aka Microbiota as a Therapy)!

OUR AMBITION: to embody a new medical paradigm

Since its creation at the end of 2014, MaaT Pharma has undergone exponential development. After a first fundraising round of €2 million, carried out in December 2014, MaaT Pharma has already validated the safety and the dose of its drug candidate, during pre-clinical trials carried out in 2015 in partnership with the Inra. The start-up has also just completed the prototyping of a unique solution, allowing the collection of the sampled microbiome and guaranteeing the safety of all of the players (patient, operator, medical staff) until the administration phase.

MaaT Pharma has set itself the objective of being a player in the emergence of a new medical paradigm around the role played by the intestinal microbiome in health and well-being. Its priority action lines relate to the correction of dysbiosis and associated complications, the eradication of Multi-Drug Resistant Bacteria, the prevention of nosocomial diseases, the re-establishment of key functions of the intestinal microbiome and the stimulation of the immune system and restoration of metabolic functions.

TEAM

Hervé Affagard

Hervé Affagard

Chief Executive Officer

Engineer, Executive MBA, Certificate “Exploring your Microbiome”

Hervé leads the MaaT Pharma project since its inception phase in December 2013. Hervé worked previously as an entrepreneur in residence for venture capital firms with regards to their investments in the Healthcare field. In parallel, he also used to work as a consultant for biotechnology companies where he led transformation program. He was previously an executive director leading a multidisciplinary team at Biomnis, specialist in medical testing. Combined with his previous experience at Bio-Rad which serves life science research and clinical diagnostics customers, he brings to MaaT Pharma a strong track record of operational leadership in the health sector and the capacity to translate into a concrete plan medical notions. Hervé is also a result-oriented person who led successfully projects up to €50m.

Corentin Le Camus

Corentin Le Camus

Therapeutic Development Director

PhD

Corentin Le Camus holds a PhD in pharmaco-chemistry, pharmacology and metabolism delivered by the University of Paris V. He is also an Executive MBA graduate from EM Lyon. Corentin has an International multi-area experience in clinical development, amongst which he counts more than 10 years of experience in clinical project management within big pharma companies, such as Servier, Sanofi. In this previous functions, Corentin managed from phase II to phase IV projects up to 18,000 patients. He also built-up the clinical team at Olympus Biotech from company inception.Corentin joined MaaT Pharma to lead the development of Clinical operations and to coordinate the actions between the existing team and our external advisors. He will bring his expertise in regulatory affairs and scientific matters.

Carole Schwintner

Carole Schwintner

Pharmaceutical Development Director

PhD

Carole is leading the technological developments for MaaT Pharma. After her PhD in molecular microbiology, she has worked in genetics of yeast as a post-doctoral fellow. She then turned to industry as a translational/industrialization and analytical developments manager for biotechnological process. She has held increasing responsibilities in the manufacturing activities for medical diagnostics in a top 10 company, including supply, scheduling, production, quality control, quality and manufacturing supports in GMP environment. In 2013, she entered a start-up structure dedicated to glycosylated proteins, before joining MaaT Pharma in 2015.

Main Co-Founders

Hervé Affagard

Hervé Affagard

Chief Executive Officer

Engineer, Executive MBA, Certificate “Exploring your Microbiome”

Hervé leads the MaaT Pharma project since its inception phase in December 2013. Hervé worked previously as an entrepreneur in residence for venture capital firms with regards to their investments in the Healthcare field. In parallel, he also used to work as a consultant for biotechnology companies where he led transformation program. He was previously an executive director leading a multidisciplinary team at Biomnis, specialist in medical testing. Combined with his previous experience at Bio-Rad which serves life science research and clinical diagnostics customers, he brings to MaaT Pharma a strong track record of operational leadership in the health sector and the capacity to translate into a concrete plan medical notions. Hervé is also a result-oriented person who led successfully projects up to €50m.

Dr Pierre Belichard

Dr Pierre Belichard

Non executive president of the Board

PharmD, PhD, MBA from INSEAD

Pierre Belichard is also founder and CEO of Enterome Bioscience. VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by Sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma.

Dr Joël Doré

Dr Joël Doré

Scientific Advisor

PhD in Intestinal Microbiology

Joël is a research Director at INRA and also a Scientific Director of MetaGenoPolis (mgps.eu), a Unit of the Micalis Institute “Food and Gut Microbiology for Human Health”. He joined INRA in 1983 and received his PhD from the University of Illinois at Urbana-Champaign, USA, in 1988. He trained as gut microbial ecologist and developed expertise in intestinal metagenomics towards diagnostic and prognostic applications as well as food-microbe-host interactions. Joël aims to contribute to a better understanding of the intestinal ecosystem in order to support therapeutic choices in the medical area, as well as science-based recommendations in health nutrition. Joël Doré chairs the gutmicrobiotaforhealth.com scientific web-platform.

Pr Mohamad Mohty

Pr Mohamad Mohty

Medical haematology-oncology Advisor

MD, PhD

Mohamad Mohty is Professor of Hematology and Head of the Hematology Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France). He obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. He is also Head of a translational research team (INSERM U938, team N°7) at the Saint-Antoine Research centre in Paris. He is currently president of the European Society for Blood and Marrow Transplantation (EBMT). He is a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation (ASBMT), and European Hematology Association (EHA).

Dr Pierre Rimbaud

Dr Pierre Rimbaud

Medical Advisor

MD

Pierre is a co-founder of several companies, apart from MaaT Pharma, involved in the field of nutrition and gut microbiome (Enterome Bioscience, Indigo Therapeutics, Targedys); previously, after practicing and teaching medicine for years, he had created a company (Jenwin Consulting) specialized in pharmaceutical development and healthcare marketing, and became a regular counselor for Seventure Partners and Health for Life Capital.

Board Of Directors

Hervé Affagard

Hervé Affagard

Administrator

Engineer, Executive MBA, Certificate “Exploring your Microbiome”

Hervé leads the MaaT Pharma project since its inception phase in December 2013. Hervé worked previously as an entrepreneur in residence for venture capital firms with regards to their investments in the Healthcare field. In parallel, he also used to work as a consultant for biotechnology companies where he led transformation program. He was previously an executive director leading a multidisciplinary team at Biomnis, specialist in medical testing. Combined with his previous experience at Bio-Rad which serves life science research and clinical diagnostics customers, he brings to MaaT Pharma a strong track record of operational leadership in the health sector and the capacity to translate into a concrete plan medical notions. Hervé is also a result-oriented person who led successfully projects up to €50m.

Dr Pierre Belichard

Dr Pierre Belichard

Non executive president of the Board

PharmD, PhD, MBA from INSEAD

Pierre Belichard is also founder and CEO of Enterome Bioscience. VP M&A and business development at Sanofi Ophthalmology, Pierre was the founder and COO of Fovea Pharmaceuticals and has been instrumental in building up the product-portfolio that became the Ophthalmology division of Sanofi (Fovea was acquired by Sanofi in 2009 for €370m, less than five years after inception). Earlier, Pierre was VP Business Development at UroGene, a company sold to Pierre Fabre in 2004. In 2000, he took over the position of head of European commercial operations at Ethypharm. Prior to this, Pierre held various positions in science and business development at Fournier Pharma.

Isabelle de Crémoux

Isabelle de Crémoux

Administrator

Isabelle de Cremoux is the President and CEO of Seventure Partners and manages the Life Sciences team. Seventure Partners is a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, industrial biotechnologies/cleantech and nutrition. The specific ‘core’ of Seventure’s investment strategy is ‘nutrition, health and wellness’, with particular focus on the intestinal microbiome. Formerly, Isabelle started her career in ’91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development. Since ’98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the life sciences department. Isabelle leads the life sciences team and makes direct investments, mainly in France and Scandinavia with a focus on biotech, nutrition, personalized medicine and especially microbiome. Isabelle’s trackrecord includes Santaris (sold to Roche for $450 millions in august 2014), argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

Eric de la Fortelle

Eric de la Fortelle

Administrator

Dr. Eric de La Fortelle is a Venture Partner in the Life Sciences Team of Seventure Partners, a Paris-based venture capital organization focused on innovation in life sciences and ICT. The broad focus areas within life sciences are therapeutics, medical devices, industrial biotechnologies/cleantech and nutrition. The specific ‘core’ of Seventure’s investment strategy is ‘nutrition, health and wellness’, with particular focus on the intestinal microbiome. Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations). Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and Physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA (honors) from INSEAD.

Karine Lignel

Karine Lignel

Administrator

Engineer

Karine LIGNEL is an Engineer (food science, ENSIA with a Master’s degree in finance and economics (IGIA, part of ESSEC). She has seven years of experience in the food industry, mainly in technical positions. She joined venture capital since 2000, investing mainly in life sciences. Since 2000, she has been appointed to more than 20 board memberships. CM-CIC Innovation is a subsidiary of CM-CIC Investissement, the Crédit Mutuel – CIC group’s investment and merchant bank division. With more than 2.6 billion Euros worth of equity under management and over 600 portfolio companies, CM-CIC Investissement is a key player in capital investment in France, backed by its own equity resources.

CM-CIC Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, information technology, industrial innovations or environment.

Karine is the CEO of the Venture Capital team at CM-CIC Innovation, which has an active portfolio of 35 companies. Her field of expertise is fast-growing technological companies. She has chosen and invested in more than 15 companies and helped manage more than 40 companies, working with them on their strategic plans. She has been heavily involved in multiple refinancing rounds and has been key in three industrial exits as well as two successful IPOs. Karine has a Food Engineer Degree from ENSIA, Massy, as well as an MBA in Finance and Accounting from IGIA, Cergy.

Jean-Marie Lefevre

Jean-Marie Lefevre

Administrator

Engineer, MBA

Jean-Marie Lefevre is CEO of Biocodex, a multinational research and development, manufacturing and marketing company, specialised at an International level in the therapeutic domains of gastroenterology, neuropsychiatry and pain treatment. Jean-Marie Lefevre has a long-track record in the function of Chief Executive Officer.

Consultant in strategy at the beginning of his career at the Boston Consulting Group in Paris and Chicago, he cofounded Spizza 30, before joining the Bongrain group, where he was appointed CEO of Scandinavian Fish Co and Nutrimer. In 1994, he integrated the LVMH group and joined the PommeryChampagne, where he became CEO. In 2000, he left the Group to develop some entrepreneurial projects. He worked briefly at Aoste Group before rallying Biocodex which, under his leadership, is experiencing a new boom with a workforce growing from 250 to 960 employees.

Julien Samson

Julien Samson

Administrator

Julien Samson was appointed Vice-President – Commercial Operations Pharmaceuticals for GlaxoSmithKline France in October 2012. He has been member of the Respiratory Franchise Board of GSK at global level since March 2015. He was Deputy General Director of the Academic Medical Center of Lyon (2009-2012), social welfare technical adviser to Mr. Nicolas Sarkozy, President of the French Republic (2007-2009) and to Mr. Thierry Breton, Minister of Economy, Finance & Industry, and Mr. Jean-François Copé, Minister for the Budget and State Reform & Government Spokesman (2005-2007), and was responsible for healthcare and solidarity policies for the Directorate of Budget of the ministry of Finances (2002-2005). Julien was vice-president of the Scientific Council for the National Agency to boost Hospital Performance (2009-2013). Graduate of the Institute of political studies of Paris (1998), he is an alumnus of the National School of Administration (2002). He published four books: Managing hospital (2012), Political economy of the organic law on Budget Acts (2007), Propositions for a reform of the fiscal governance (2005) and The police headquarters in the service of the Parisians (2000).

Philippe Lénée

Philippe Lénée

Censor

Dr Philippe Lenee, PhD in biotechnology and agronomy engineer has twelve years of experience in research in biotechnology in a private seed company and four years of executive management as operations director of a food factory. From 2003, he became CEO of INRA Transfert, the INRA subsidiary in charge of technology transfer of innovations and management of European R&D projects. His responsibilities encompassed: setting up and management of national and European R&D projects, technology transfer and commercialization of INRA innovations, business intelligence and partnerships with industry in the economic sectors of health and food safety, animal health, food, plant and animal production, environment and animal and plant biotechnology.

Investors

About Seventure Partners

With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, especially fintech & assurtech, in France and Germany, and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more information, please visit: www.seventure.com

 

About CM-CIC

CM-CIC Innovation is a subsidiary of CM-CIC Investissement, the Crédit Mutuel – CIC group’s investment and merchant bank division. With more than 2.6 billion Euros worth of equity under management and over 600 portfolio companies, CM-CIC Investissement is a key player in capital investment in France, backed by its own equity resources.

CM-CIC Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, information technology, industrial innovations or environment. 

For more details:

CM-CIC Innovation is a subsidiary of CM-CIC Investissement, the Crédit Mutuel – CIC group’s investment and merchant bank division. With more than 2.6 billion Euros worth of equity under management and over 600 portfolio companies, CM-CIC Investissement is a key player in capital investment in France, backed by its own equity resources.

CM-CIC Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, information technology, industrial innovations or environment.

For more information,  please visit: http://www.cmcic-­investissement.com

 

About Biocodex

Biocodex is an independent family-owned pharmaceutical company, founded in Paris, France in 1953. The company initially concentrated on gastroenterology and specifically on the discovery of a promising probiotic substance, Saccharomyces boulardii (sold under the ULTRA-LEVURE brand in France). Biocodex has maintained partnerships with health sector professionals for 60 years, with the mission of developing intelligent solutions that respond to contemporary healthcare issues. Biocodex has become a multinational research and development, manufacturing and marketing company. The company is currently active in over 100 countries, with subsidiaries in Belgium, Russia, Ukraine, Turkey, Morocco, Mexico, the United States and through partnerships with distributors. Today, Biocodex specialises at international level in the therapeutic domains of gastroenterology, neuropsychiatry and pain treatment.

For more information, please visit:  www.biocodex.fr/en/

About INRA Transfert

The INRA Transfert portfolio counted 420 active licenses of patent, know-how and software exploitation for an annual turnover of royalties over 4 M€. INRA Transfert manages 30 major European programs coordinated by INRA. INRA Transfert, the INRA subsidiary, is a company focused on project engineering and management of technology transfer to foster food, agricultural and environmental innovation. INRA Transfert enhances and manages the INRA technology portfolio through operating agreements with manufacturers and supports the development of innovative young companies.

As an intermediary between research and business world, INRA Transfert has five main missions:

  • Transferring research results to companies by promoting and managing INRA’s portfolio of technologies, through operating agreements with the industrial sector.
  • Promoting the creation of innovative companies, by supporting their development
  • Supporting the setup, negotiation and management of European or national collaborative research projects by means of our expertise in project engineering.
  • Setting up and managing large partnership research programs
  • Providing resources to support innovation.

For more information,  please visit: http://www.inra-transfert.fr/en/

440px-Maat.svg

 

MaaT is originally the name of the goddess of balance, truth and order in Ancient Egypt. These notions ruled over the entire Egyptian society.

This mythological reference illustrates on the one hand at the level of human individuals the phenomenon of microbiota-host symbiosis (balance) and, on the other hand at the broader level of humanity, our team’s intention to embrace a societal project designed to deeply change our contemporary medical field.

MaaT also stands for Microbiota as a Therapy implying a very innovative way of curing people and preventing diseases by using their gut microbiota.